J&J-backed Delix secures $100M for non-hallucinatory psychedelic
Delix Therapeutics has raised $100 million in a series C round backed by the likes of Johnson & Johnson to advance a phase 2-ready non-hallucinatory psychedelic therapy for depression.
Boston-based neuroscience company developing neuroplasticity-promoting therapeutics for CNS diseases including depression and PTSD, built on non-hallucinatory psychoplastogen chemistry.
Delix Therapeutics has raised $100 million in a series C round backed by the likes of Johnson & Johnson to advance a phase 2-ready non-hallucinatory psychedelic therapy for depression.
Co-founder